Retension Pharmaceuticals, Inc. has disclosed a change in beneficial ownership in its latest SEC filing. This event is significant as it reflects the ongoing dynamics within the pharmaceutical preparations industry, where ownership changes can signal shifts in strategy or investor confidence.
Company Overview
Retension Pharmaceuticals, Inc. operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker RTSN. As an emerging growth company, Retension is focused on developing innovative pharmaceutical solutions.
What the Filing Says
The SEC filing, dated October 8, 2026, indicates a change in beneficial ownership but does not provide specific details regarding the nature of the changes. The filing states, "Statement of changes in beneficial ownership of securities." Details were not available in the SEC filing.
Impact
This change in ownership may affect various stakeholders, including investors and company executives. Changes in beneficial ownership can influence market perceptions and investor strategies, particularly in the competitive landscape of pharmaceutical preparations.
What's Next
The filing does not say what happens next. However, stakeholders will likely be monitoring further developments from Retension Pharmaceuticals as they continue to navigate the complexities of the pharmaceutical industry.
Details of the Reporting Person
The filing identifies Michael J. Berendt as the reporting person, who is associated with Retension Pharmaceuticals, Inc. This designation indicates his role in the company, which may involve significant decision-making responsibilities affecting the company's direction.
Filing and Acceptance Dates
The Form 4 was filed on October 8, 2026, and was accepted on the same day at 21:39:50. This prompt acceptance suggests that the SEC reviewed and processed the filing without delays, which can be indicative of the accuracy and completeness of the information submitted.
Company Information
Retension Pharmaceuticals, Inc. is incorporated in Delaware and operates under the EIN 932592788. The company focuses on pharmaceutical preparations, as indicated by its SIC code 2834, and is classified under the CF Office for Life Sciences. The fiscal year for the company ends on December 31.
Missing Information
While the filing indicates a change in beneficial ownership, it does not specify the number of shares involved, the price at which the shares were acquired or disposed of, or the overall impact on the ownership structure of the company. Additionally, there is no mention of the reason behind the change in ownership, which could provide further context for stakeholders.